Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.13 Consensus Price Target from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been given an average recommendation of “Buy” by the twelve research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $14.56.

CATX has been the topic of a number of recent analyst reports. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Friday, January 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $2.59 on Monday. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05. The firm’s 50 day moving average price is $3.14 and its two-hundred day moving average price is $7.20.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. US Bancorp DE grew its stake in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at about $153,000. WealthPlan Investment Management LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $4,530,000. Victory Capital Management Inc. increased its holdings in Perspective Therapeutics by 328.7% in the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock worth $674,000 after buying an additional 38,690 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new position in Perspective Therapeutics during the third quarter valued at approximately $259,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.